NorthCoast Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

NorthCoast Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,427	Closed	-$262K	–	465
2021 Q2	$262K	Buy	1,427 +33	+2%	+$5.67K	0.01%	397
2021 Q1	$213K	Buy	+1,394	New	+$216K	0.01%	394
2020 Q4	–	Sell	-8,618	Closed	-$986K	–	404
2020 Q3	$986K	Sell	8,618 -1,183	-12%	-$128K	0.05%	187
2020 Q2	$1.1M	Buy	+9,801	New	+$1.04M	0.06%	165

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

NorthCoast Asset Management's ALXN Position: Q3 2021 in Review

NorthCoast Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,427 shares — an estimated $262K sold.

NorthCoast Asset Management first reported a position in ALXN in Q2 2020 and held it in 4 quarters. The position peaked at $1.1M in Q2 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

NorthCoast Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
NorthCoast Asset Management sold 1,427 Alexion Pharmaceuticals shares in Q3 2021, an estimated $262K.
NorthCoast Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 4 quarters.
NorthCoast Asset Management's Alexion Pharmaceuticals position peaked at $1.1M in Q2 2020.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on NorthCoast Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.